Adachi, Jonathan D.
Berger, Claudie
Barron, Rich
Weycker, Derek
Anastassiades, Tassos P.
Davison, K. Shawn
Hanley, David A.
Ioannidis, George
Jackson, Stuart A.
Josse, Robert G.
Kaiser, Stephanie M.
Kovacs, Christopher S.
Leslie, William D.
Morin, Suzanne N.
Papaioannou, Alexandra
Prior, Jerilynn C.
Shyta, Erinda
Silvia, Amanda
Towheed, Tanveer
Goltzman, David
Article History
Received: 7 November 2018
Accepted: 7 April 2019
First Online: 16 May 2019
Compliance with ethical standards
:
: Rich Barron was employed by Amgen Inc. during the conduct of this study and owns stock in Amgen Inc. Derek Weycker and Amanda Silvia are employed by PAI; Erinda Shyta was employed by PAI during the conduct of this study. Jonathan D. Adachi has grants and personal fees with Amgen Inc. and personal fees with Eli Lilly. K. Shawn Davison has speaker honoraria with Amgen Inc. David A. Hanley has a research grant and speaker honoraria with Amgen Inc. Robert G. Josse has consultancy fees and a speaking honoraria with Amgen Inc. and Merck. Stephanie M. Kaiser has consultancy fees and speaking honoraria with Amgen Inc. Christopher S. Kovacs has an honorarium with Amgen Inc. Suzanne N. Morin has research grants with Amgen Inc. and Merck. Tanveer Towheed has an honorarium and speaker fees with Amgen Inc. Tassos P. Anastassiades, Claudie Berger, David Goltzman, George Ioannidis, Stuart A. Jackson, William D. Leslie, Alexandra Papaioannou, and Jerilynn C. Prior have no conflicts of interest for this work.